Once-daily treatment for canine atopic dermatitis
Delivers 6-in-1 parasite protection for cats
Valuable discounts, expert information, and tips
See how injectable medications offer value beyond the prescription
The first and only FDA-Approved veterinary antiemetic
The first long-lasting monoclonal antibody therapy for canine atopic dermatitis
Vaccination for the prevention of respiratory disease caused by BRSV
The beef industry’s No. 1 branded preconditioning program
Exclusive pricing program for Cattle producers
Outstanding protection against costly respiratory and reproductive diseases
Treatment and control of gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
Innovative food safety products that help deliver a farm-to-fork solution for beef
The most comprehensive guarantee available
First and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses
Annual vaccination with CORE EQ INNOVATOR helps provide the protection your horse needs
Treats and controls encysted small strongyles, bots and roundworms. QUEST PLUS contains an additional active ingredient for efficacy against tapeworms
Patented and scientific method of determining fair service pricing to improve your clinic's profitability
Connect directly to valuable dairy management resources and experts
The most "veterinarian recommended" and "producer used" prostaglandin in the market
Delivers the peace of mind and profitability that come with no milk discard
Effective and convenient treatment for acute metritis in cattle
Working together to improve reproduction
One injection treats and controls swine respiratory disease for 7 days
Protect sows and gilts from costly breeding herd diseases — parvovirus, leptospirosis and erysipelas
The industry standard for in ovo technology.
Full automation solutions for hatchery automation
Prevention and control of necrotic enteritis, increased rate of weight gain and improved feed efficiency in poultry
for the prevention of coccidiosis in poultry
modified-live vaccine that helps poultry companies reduce their overall Salmonella load
Blood glucose monitoring system
Smart new diagnostics platform that can reinvent your in-house diagnostic routines
Detect Johne’s Disease with confidence in cattle and goat herds
Simple and effective detection of a deadly Feline Virus
Accurate, affordable and easy to use
Order Beef Genetics products online
Order Dairy Genetics products online
Delivers reliable predictions of genetic merit based on test results of core traits
Represents the latest advancement in Angus genotyping technology.
Register today to learn more
Become a more effective leader
Looking for a tailored experience?
Earn continuing education credits and stay current on industry developments with Zoetis’ convenient, on-demand learning solutions.
Veterinarians, Veterinarian Techs, Business Owners, and Farm Hands
Launch your veterinary career
Veterinarian Students and Recent Graduates
Animal health expertise and results-focused resources for high-performing teams and leaders.
Veterinarians, Dairy producers, Beef producers, Equine Specialists, Pork producers, Poultry producers, Managers, Business Owners and Staff
Home / NEWS & MEDIA / Zoetis Receives a Conditional License from USDA for Canine Atopic Dermatitis Immunotherapeutic
First targeted antibody therapy approved for control of clinical signs of atopic dermatitis in dogs
FLORHAM PARK, N.J. – Aug. 3, 2015 – Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic,* a first-of-its-kind antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. It represents another major innovation to emerge from the proprietary research and development platform Zoetis has built based on new scientific insights into the pathway of allergic skin conditions.
“The introduction of Canine Atopic Dermatitis Immunotherapeutic* will provide veterinarians an innovative new option to address this very challenging skin condition,” said Thomas Lewis II, DVM, DACVD, who participated in clinical studies of this antibody therapy and is a veterinary dermatologist at Dermatology for Animals in Gilbert, Ariz.** “By helping to relieve itching and the clinical signs associated with atopic dermatitis in affected dogs, it will also help restore quality of life for both atopic dogs and the people who love them.”
This novel therapy contains an antibody that specifically targets and neutralizes interleukin-31 (IL-31), a key protein that is responsible for sending the itch signal to the brain. It will be available in a ready-to-use, sterile liquid administered as a once-monthly subcutaneous injection and will help provide sustained relief from the itching associated with atopic dermatitis in dogs of any age.
“We have been active in building a research platform in monoclonal antibodies that will have a broad application across species and medical conditions,” said Catherine Knupp, executive vice president and president, Research and Development at Zoetis. “This first product from that platform builds on our knowledge base in the area of canine dermatology and further reinforces our dedication to developing innovative dermatology solutions.”
The USDA has communicated that all biological products for canine atopic dermatitis will be considered for conditional licensure only at this time. Zoetis is working with the USDA to obtain full licensure.
Zoetis will make Canine Atopic Dermatitis Immunotherapeutic* available primarily to veterinary dermatology specialists early in the fourth quarter of 2015 to gain more experience with this first antibody therapy in canine dermatology and acquire a deeper understanding of how veterinarians will use it in clinical practice. This will help the company prepare for full licensure. As the timing for full licensure becomes certain, the approach and timing for launch to veterinarians nationwide will be set.
About Atopic Dermatitis and Canine Atopic Dermatitis Immunotherapeutic*Itching is among the most frequent complaints of pet owners, affecting roughly 1 in 6 dogs whose owners seek veterinary help.*** There are a number of factors that can trigger an itch reaction, such as infections, otitis and parasites—and approximately 15-20 percent of all itchy dogs will be diagnosed with atopic dermatitis.*** Canine Atopic Dermatitis Immunotherapeutic* works by mimicking the specific activity of natural antibodies by selectively binding and neutralizing IL-31 and interrupting the itch cycle.
Canine Atopic Dermatitis Immunotherapeutic* has been demonstrated to be safe and effective in helping decrease itching within one day and maintains efficacy for one month. Dosing can be repeated monthly as necessary, and reported adverse reactions to the product were similar to those of a placebo.
About ZoetisZoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenues of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetis.com.
DISCLOSURE NOTICESForward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, expectations regarding products, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com or on request from Zoetis.
For Further Information,Contact:
Elinore White email@example.com
*This product license is conditional. Efficacy and potency test studies are in progress.
*** Data on file, IL-31 Positioning Research. IPSOS 2014. IL-31 Pricing Research. SKP. 2015, Zoetis Inc.
Multimedia Files:Download All Files
Dog with veterinarian. Source: Zoetis Inc.
Download: Download Thumbnail (4.51 KB) Download Preview (6.89 KB) Download Small (24.93 KB) Download Full Size (45.7 KB) Download Square (8.53 KB)
Video: Cytokine IL-31 - A Critical Mediator of Canine Atopic Skin Disease. Canine Atopic Dermatitis Immunotherapeutic is conditionally licensed. Efficacy and potency tests are in progress. Source: Zoetis Inc.
Download:Download Thumbnail (6.58 KB) Download Preview (18.67 KB) Download Square (29.99 KB) Download Full Size (209.79 KB) Download Windows Media Video (23.15 MB) Download Quicktime (17.51 MB) Download MPEG-4 Video (19.21 MB)
Novel Monoclonal Antibody Selectively Binds and Neutralizes Cytokine IL-31 in Dogs. Source: Zoetis Inc.
Download:Download Thumbnail (23.48 KB) Download Preview (38.74 KB) Download Small (177.61 KB) Download Full Size (2.34 MB) Download Square (44.2 KB)
Download: Download Thumbnail (33.64 KB) Download Preview (36.63 KB) Download Small (71.96 KB) Download Full Size (125.87 KB)Download Square (36.49 KB)
Mon–Fri, 8am–8pm ET
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
This site is intended for U.S. Animal Healthcare Professionals.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2017 Zoetis Services LLC. All rights reserved.